CVS Health account plan
Comprehensive community health support
At a glance
CVS Health is a U.S. health solutions company: Aetna insurance, the CVS Caremark PBM, about 9,000 pharmacies and 1,000+ clinics; $402.1 billion 2025 revenue.
CVS Health is a U.S. health solutions company that combines a health insurer (Aetna, serving an estimated more than 37 million people), a pharmacy benefits manager (CVS Caremark, approximately 87 million plan members), approximately 9,000 retail locations and more than 1,000 walk-in and primary care clinics. Its customers are consumers, employers, health plans and government programs; the U.S. federal government is a major customer, with Health Care Benefits revenues from it at approximately 20% of consolidated total revenues in 2025. In fiscal 2025 total revenues were $402.1 billion (+7.8%), adjusted operating income $14.4 billion and net income attributable to CVS Health $1.8 billion, after a $5.7 billion goodwill impairment on Health Care Delivery. It employs over 300,000 colleagues, primarily in the U.S., and is headquartered in Woonsocket, Rhode Island. The company does not plan to expand internationally.
Business units
Health Care Benefits (Aetna)
$143.4 billion total revenues in 2025 (before intersegment eliminations)Insured and self-funded medical, pharmacy, dental and behavioral health plans for employers, individuals and government programs, including Medicare Advantage, standalone Medicare Part D and Medicaid; medical membership was 26.6 million at end-2025. Adjusted operating income recovered to $2.9 billion from $307 million as the medical benefit ratio improved to 91.2% from 92.5%, and Aetna exited the individual Public Exchanges effective January 2026. Led by Steven H. Nelson, EVP and President, Aetna.
Health Services (CVS Caremark, health care delivery, Cordavis)
$190.4 billion total revenues in 2025 (before intersegment eliminations)The CVS Caremark PBM (formulary management, a network of approximately 63,000 retail pharmacies, mail order and specialty pharmacy; 1.9 billion claims processed in 2025), the Cordavis biosimilars business, and health care delivery through Oak Street Health, Signify Health and more than 800 MinuteClinic locations. Revenue grew 9.7% in 2025 while adjusted operating income fell 1.3% to $7.2 billion on client price improvements and higher care delivery costs. Caremark is led by Ed DeVaney, President, Pharmacy Services; Health Care Delivery by Sree Chaguturu.
Pharmacy & Consumer Wellness (CVS Pharmacy)
$139.4 billion total revenues in 2025 (before intersegment eliminations)About 9,000 retail locations, including approximately 1,870 pharmacies inside retail chains (primarily Target), plus infusion and enteral nutrition branches; it dispensed approximately 28.5% of U.S. retail prescriptions. Revenue grew 11.9% in 2025 with pharmacy same store sales +18.0%, helped by branded GLP-1s and Rite Aid prescription file acquisitions; adjusted operating income was $6.0 billion. Led by Len Shankman, President, Pharmacy & Consumer Wellness.
Corporate/Other
$484 million total revenues in 2025Corporate functions (executive management, legal, compliance, HR, finance, IT, digital, data and analytics) and closed books such as large case pensions and long-term care insurance. The adjusted operating loss was $1.7 billion in 2025, widened by investments in colleagues and capabilities.
Strategic priorities
- Aetna margin recovery
- After adding $2.5 billion of operating income in 2025, Aetna targeted adjusted operating income of $3.6-$3.9 billion for 2026 with a medical benefit ratio of 90.5% +/- 50 bps, helped by the exit from the individual exchange business.
- Mid-teens earnings growth through 2028
- At the December 2025 Investor Day management set a mid-teens adjusted EPS CAGR through 2028, with growth from every business and not counting buybacks or the upside from the new open engagement platform.
- Technology-powered consumer engagement
- CVS made a $20 billion commitment to technology over 10 years, is building an integrated CVS Health app across Aetna, Caremark, CVS Pharmacy and MinuteClinic, and plans an open engagement platform that other PBMs, payers and providers could plug into.
- Partner of choice for providers
- One of the four strategic pillars is to be the partner of choice for providers by addressing prior authorization, administrative complexity and interoperability; Caremark reports 90% of prior authorizations approved within 24 hours.
- Lowest net cost and specialty leadership at Caremark
- Caremark prioritises lowest net cost, transparency and specialty, with TrueCost net-cost drug-level pricing covering more than 12,000 drugs and biosimilars seen growing from approximately a $10 billion market to more than $100 billion by decade end.
- Margin over growth in care delivery and retail
- Oak Street Health has shifted from clinic growth to margin improvement, targeting mid to high single-digit margins long term, while CVS Pharmacy now aims for at least flat earnings each year and is moving almost 500 of 900 MinuteClinics to primary care capacity.
Latest results
In Q2 2026 (three months to June 30, 2026) total revenues rose 7.3% to $106.1 billion, with growth in all operating segments, and adjusted operating income rose 35.4% to $5.2 billion. GAAP diluted EPS was $2.31 (Q2 2025: $0.80) and adjusted EPS $2.58 ($1.81), mainly from Aetna, whose adjusted operating income rose 85.5% to $2.4 billion as the medical benefit ratio improved to 87.4% from 89.9%. Health Services revenue grew 11.5% to $51.8 billion and Pharmacy & Consumer Wellness adjusted operating income rose 10.2%, with prescriptions filled +4.3%. Full-year 2026 guidance was raised to total revenues of at least $414.0 billion, adjusted EPS of $7.90-$8.10 (from $7.30-$7.50) and cash flow from operations of at least $11.5 billion, while management keeps "a cautious view" given elevated cost trends and possible macro headwinds.
Investments and deals
- Technology and digital capex
- Gross capital expenditures were approximately $2.8 billion in 2025, 77% of it for technology, digital and other strategic initiatives; capex is planned at around $3 billion a year, within a $20 billion technology commitment over 10 years.
- Rite Aid assets and prescription files
- CVS acquired Rite Aid prescription files and Rite Aid stores in Idaho, Oregon and Washington ($465 million total consideration), completed in Q3 2025; management cites 63 Pacific Northwest stores and over 600 file buys.
- Agentic AI in operations
- Agentic AI is being deployed in Aetna and CVS Caremark call centers, and the second-generation Aetna Claims Assist Manager cuts processing time by over 20% for complex claims needing manual review.
- Portfolio exits and store footprint
- In 2025 CVS sold its MSSP business, wound down ACO REACH, deconsolidated Omnicare after its Chapter 11 filing, exited the individual exchanges, and closed 243 stores while opening or acquiring 87.
- Deleveraging
- No share repurchases in 2025 or 2026 while the company deleverages to a mid-BBB rating; $4.0 billion of senior notes were issued in August 2025 and the quarterly dividend of $0.665 is expected to be maintained through 2026.
Challenges and risks
- Elevated medical utilization
- Utilization is expected to stay elevated in 2026 and could pressure Aetna and the care delivery assets; value-based care is described as being in "a trough period".
- PBM regulation and pricing pressure
- Comprehensive PBM legislation is proposed or enacted in a majority of states and federally, with more rebates passed to clients, limits on spread pricing and a risk of laws barring PBM-affiliated pharmacies.
- Government funding and rates
- CVS depends on Medicare and Medicaid funding, rates, risk adjustment and star ratings; CMS proposed a 0.09% average 2027 Medicare Advantage rate increase, and the CEO names government's role as his biggest challenge.
- Care delivery write-downs
- A $5.7 billion goodwill impairment hit Oak Street Health and Signify Health in 2025; $4.2 billion of goodwill remains and further impairment is "reasonably possible".
- Litigation and credit outlook
- About $1.2 billion of legacy litigation charges and a $320 million opioid charge were taken in 2025, and debt ratings carry a negative outlook at Fitch and S&P.
What leadership says
“We righted the ship, charted a new path forward, and now entering parts of the market that either others can't and/or simply are not equipped to be able to compete.”
“technology will become the enabler for our growth.”
“As our businesses work together to deliver a technology-powered care engagement experience, we continue to deliver strong performance.”
“We have 500 million phone calls a year into the pharmacy”
Where a supplier can help
- Call deflection and conversational AI
- Tied to the technology-powered consumer engagement priority and the agentic AI investment: with 500 million pharmacy calls a year, suppliers of conversational AI, self-service and prescription status tooling can help take calls out of the system.
- Provider friction and prior authorization
- Tied to the partner-of-choice priority: vendors in prior authorization automation, interoperability and claims processing can support CVS's push to cut administrative complexity for providers.
- Care delivery cost efficiency
- Tied to the care delivery margin priority and the goodwill impairment challenge: Oak Street's shift to margin improvement favours suppliers that lower clinic operating costs or improve risk-adjustment accuracy.
- Medical cost management for Aetna
- Tied to the Aetna margin recovery priority and the elevated utilization challenge: analytics, trend forecasting and care navigation offerings that help hold the medical benefit ratio are directly relevant.
- Regulatory and compliance support
- Tied to the PBM regulation and litigation challenges: compliance, transparency reporting and pricing-model tooling can help Caremark operate under state and federal PBM rules.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like CVS Health?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Annual Report on Form 10-K for fiscal 2025 (year ended December 31, 2025)
- CVS Health is a U.S. "health solutions company": approximately 9,000 retail locations, more than 1,000 walk-in and primary care medical clinics, a PBM (CVS Caremark) with approximately 87 million plan members, and Aetna health insurance serving an estimated more than 37 million people; over 300,000 colleagues.
- 2025 total revenues $402.1 billion (+7.8%), with growth in all operating segments; adjusted operating income $14.4 billion (2024: $12.0 billion), but GAAP operating income fell 45.3% to $4.7 billion and net income attributable to CVS Health to $1.8 billion.
- The drop came from a $5.7 billion goodwill impairment on the Health Care Delivery reporting unit (Oak Street Health and Signify Health), about $1.2 billion of legacy litigation charges (Omnicare False Claims Act case, PBM DIR reporting case) and a $320 million opioid litigation charge.
- Aetna recovery: Health Care Benefits adjusted operating income rose to $2.9 billion from $307 million as the medical benefit ratio improved to 91.2% from 92.5%; medical membership 26.6 million. Aetna exited the individual Public Exchanges effective January 2026; more than 81% of Medicare Advantage members are in plans rated 4+ stars for 2026 (88% for 2025).
- Health Services (Caremark PBM, Oak Street, Signify, MinuteClinic, Cordavis) revenue $190.4 billion, 1.9 billion claims processed; Pharmacy & Consumer Wellness revenue $139.4 billion with pharmacy same store sales +18.0%, helped by branded GLP-1s and Rite Aid prescription file acquisitions.
- Restructuring of the footprint: 243 stores closed and 87 opened in 2025; Omnicare (long-term care pharmacy) filed Chapter 11 and was deconsolidated in September 2025; ACO REACH and MSSP exited; fewer new Oak Street clinics from 2026.
- Capex about $2.8 billion, 77% of it for technology, digital and strategic initiatives; no share buybacks in 2025; quarterly dividend held at $0.665; debt rated BBB/Baa3/BBB with negative outlooks at Fitch and S&P.
- AI is used to minimise provider/payer friction, enable consumer self-service through AI assistants and streamline operations; key risks are elevated utilization, PBM regulation in a majority of states and federally, Medicare/Medicaid funding and rate changes, and legacy litigation.
- CVS Health reports second quarter 2026 results and raises full-year 2026 guidance (earnings release, Q2 2026)
- Q2 2026 total revenues $106.1 billion (+7.3%), growth in all operating segments; GAAP diluted EPS $2.31 (Q2 2025: $0.80) and adjusted EPS $2.58 ($1.81); adjusted operating income $5.2 billion (+35.4%).
- Full-year 2026 guidance raised: total revenues at least $414.0 billion; adjusted EPS $7.90-$8.10 (from $7.30-$7.50); GAAP EPS $6.84-$7.04; cash flow from operations at least $11.5 billion (from $9.5 billion). Management keeps "a cautious view" given elevated cost trends and possible macro headwinds.
- Aetna (Health Care Benefits): adjusted operating income $2.4 billion (+85.5%), MBR 87.4% (89.9%), medical membership 26.0 million after the individual exchange exit; $1.2 billion favorable prior-year reserve development in H1.
- Health Services: revenue $51.8 billion (+11.5%), adjusted operating income $1.7 billion (+10.0%) on purchasing economics, drug mix and "modest improvement" in health care delivery; claims flat at 473.0 million.
- Pharmacy & Consumer Wellness: revenue $33.8 billion, adjusted operating income $1.5 billion (+10.2%), prescriptions filled +4.3% helped by the Rite Aid acquisitions; pharmacy same store sales +2.9%.
- Operational news: a GLP-1 support offer across CVS Pharmacy and MinuteClinic (including a $29 virtual visit), participation in the Medicare GLP-1 Bridge program, agentic AI in Aetna and Caremark call centers, and a second-generation Aetna Claims Assist Manager that cuts complex-claim processing time by over 20%.
- CVS Health 2025 Investor Day (corrected transcript)
- Joyner's message one year into the role: "We righted the ship, charted a new path forward"; four quarters delivered, executive team rebuilt, Aetna delivered $2.5 billion of operating income improvement, retail is growing instead of the -5% once guided.
- Target: a mid-teens adjusted EPS CAGR through 2028, with growth from every business; guidance philosophy is credible targets with room to outperform.
- 2026 outlook (Newman): revenue at least $400 billion, adjusted operating income $15 billion to $15.4 billion, adjusted EPS $7 to $7.20 (15% growth off a normalized 2025 base of $6.20), operating cash flow at least $10 billion; Aetna AOI $3.6-$3.9 billion with MBR 90.5% +/- 50 bps; no buybacks in 2026 while deleveraging to a mid-BBB rating.
- Four pillars: best-in-class businesses, transforming consumer experiences, partner of choice for providers, enterprise capabilities; ambition to be "America's most trusted healthcare company". $20 billion committed to technology over 10 years.
- Caremark: 2026 selling season retained more than 98% of customers and won more than $6 billion of new business; TrueCost net-cost drug-level pricing; margins "in or around 4%"; biosimilars seen growing from about $10 billion to more than $100 billion by decade end.
- CVS Pharmacy now expected to deliver at least flat earnings each year (was -5% a year); 9 million new patients served as a competitor exited, 63 Pacific Northwest stores and over 600 file buys.
- Health Care Delivery: Oak Street shifts from clinic growth to margin improvement (long-term mid to high single-digit margins); Signify did 3.5 million in-home visits; MinuteClinic added primary care in over 400 clinics.
- New "open engagement platform" and integrated CVS Health app across Aetna, Caremark, CVS Pharmacy and MinuteClinic; its upside is excluded from the financial targets.
- David Joyner in conversation with David M. Rubenstein, The Economic Club of Washington, D.C. (transcript)
- Joyner frames CVS Health as four divisions: CVS Pharmacy (9,000 pharmacies in all 50 states), the Caremark PBM, Aetna, and health care delivery (close to 1,000 clinics: MinuteClinic and Oak Street).
- His turnaround: three of four divisions were running well, so the focus has been Aetna; "we've been through two underwriting cycles" and can now predict costs and price accordingly. The next phase is making the businesses fit together for the consumer.
- Growth is not about store counts: U.S. health spend of $6 trillion in 2026 heading to $9 trillion by 2034; an ageing population needing more medication.
- MinuteClinic is becoming primary care: almost 500 of 900 MinuteClinics will have primary care capacity. He wants the 30,000 pharmacists to "practice at the top of their license" as primary care shrinks.
- Retail fixes: changed the pharmacy payment model to remove cross-subsidization, invested in technology and colleagues. Organized retail crime remains an issue.
- 500 million calls a year come into the pharmacies; reducing them through simpler processes and the app is a target. 90% of U.S. medications are generic, at an average cost around $7.
- Biggest challenge: government's role in shaping health care; four congressional hearings in three years.
- Health care data still does not flow between providers; he expects technology to change access and engagement.
Questions about CVS Health
What does CVS Health do?
CVS Health is a U.S. health solutions company that runs Aetna health insurance, the CVS Caremark pharmacy benefits manager, about 9,000 CVS Pharmacy retail locations and more than 1,000 walk-in and primary care clinics, including MinuteClinic and Oak Street Health.
What is CVS Health's revenue?
Total revenues were $402.1 billion in fiscal 2025 (+7.8%). In Q2 2026 revenues were $106.1 billion, and the company guides to at least $414.0 billion for full-year 2026.
How many employees does CVS Health have?
CVS Health employed over 300,000 colleagues at the end of 2025, approximately 73% full-time, primarily in the U.S.
Who leads CVS Health?
David Joyner has been President and CEO since October 2024 and Chair since January 2026. Brian Newman is CFO and Steven Nelson is President of Aetna.
What is CVS Health's strategy?
The ambition is to be "America's most trusted healthcare company", built on four pillars: best-in-class execution, transforming consumer experiences, being the partner of choice for providers, and enterprise capabilities connected by technology. The financial target is a mid-teens adjusted EPS CAGR through 2028.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)